

References

1. Denisyuk VI, Ivanov VP. Logos, 2001.206p (in Ukr).
2. Iskenderov BG, Lohina TV, Liusov VA, Kapelovich TYu. *Rossiyskiy cardiologicheskiy journal – Russian Journal of Cardiology* 2006;1:22–26.
3. Kovalenko BN. Morion, 2008.1424p (in Ukr).
4. Kushakovskii MS. Foliant, 1994.176 p (in Russ).
5. Malaya LT, Ladniy AI. *Journal of the Academy of Medical Sciences* 1996;2:199–216.
6. Solovian AN. *Ukrainskii cardiologichnyi zhurnal – Ukrainian Journal of Cardiology* 2012;3:55–62.
7. Chazova IE, Dmitriyev VV, Tolpigina SN, Ratova LG. *Terapevticheskiy arhiv – Therapeutic Archive* 2001;9:50–56.
8. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study. *J Am Coll Cardiol* 2001;37:1042–1048.
9. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. ESC Guidelines for the Management of Atrial Fibrillation (2010 Version). *Eur Heart J* 2010;6:1–61.
10. Caramelo C, Ocada K, Tsai P, Schrier RW. Mechanisms of the Vascular Effect of Pressor Hormones. *Am J Cardiol* 1988;62:47G–53G.
11. Cohen A, Chauvel C. The best of 2001. Echocardiography. *Arch Mal Coeur Vaiss* 2002;95:21–28.
12. Coumel P. Autonomic influences in atrial tachyarrhythmias. *J Cardiovasc Electrophysiol* 1996;7:999–1007.
13. Coumel Ph, Leenhardt A. Antiarrhythmic drugs: how evaluated them ? *Am. Heart J* 1994;127:1119–1125.
14. Daoud EG, Bogun F, Goyal R, Harvey M, Man KC, Strickberger SA, Moradi F. Effect on atrial fibrillation on atrial refractoriness in humans. *Circulation* 1996;94:1600–1606.
15. Donald ML, Thomas JW, Eric PL. Lifetime risk for development of atrial fibrillation. The Framingham Heart Study. *Circulation* 2004;110:1041–1046.
16. Friedman HS. Heart rate variability in atrial fibrillation related to left atrial size. *Am J Cardiol* 2004;93:705–709.
17. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation – executive summary. *Eur Heart J* 2006;27:1979–2030.

18. Gerds E, Oikarinen L, Palmieri V. Correlates of left atrial size in hypertension patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. *Hypertension* 2002;30:739–743.
19. Gottdiener JS, Kitsman DW, Aurigemma GP. Left atrial volume, geometry and function in systolic and diastolic heart failure of persons > or = 65 years of age / the Cardiovascular health Study. *Am J Cardiol* 2006;97:83–89.
20. Heist EK, Ruskin JN. Atrial fibrillation and congestive heart failure: risk factors, mechanisms, and treatment. *Prog Cardiovasc Dis* 2006;48:256–269.
21. Hirsh PD, Hillis LD, Campbell WB. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. *New Engl J Med* 1981;304:685–691.
22. Kaftan AH, Kaftan O. Q-T intervals and heart rate variability in hypertensive patients. *Jpn Heart J* 2000;41:73–82.
23. Laukkanen JA, Kurl S, Eranen J, Huttunen M, Salonen JT. Left atrium size and the risk of cardiovascular death in middle-aged men. *Arch Intern Med* 2005;165:1788–1793.
24. Levy S. Epidemiology and classification of atrial fibrillation. *J Cardiovasc Electrophysiol* 1998;9:S78–82.
25. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Sevard JB, Bailey KR, Iwasaka T, Tsang TS. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. *Stroke* 2005;36:2362–2366.
26. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G. The Registry of the German Competence NETwork on Atrial Fibrillation: patients characteristics and initial management. *Europace* 2009;11:423–434.
27. Nacamura F, Minshall R, Le Breton G, Rabito S. Thromboxane A₂ mediates the stimulation of inositol 1,4,5-trisphosphate production and calcium mobilization by bradykinin in neonatal rat ventricular cardiomyocytes. *Hypertension* 1996;28:444–449.
28. Nattel S, Kneller J, Zou R, Leon LJ. Mechanisms of termination of atrial fibrillation by Class I antiarrhythmic drugs: evidence from clinical, experimental, and mathematical modeling studies. *Am J Cardiol* 2004;93:368–371.
29. Nieuwlaet R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davis DW, Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Levy S, Crijns HJ. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. *Eur Heart J* 2005;26:2422–2434.
30. Oikarinen J, Neiminen MS, Vitasalo M. Relation of Q-T interval and Q-T dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE Study. The Losartan intervention. For Endpoint Reduction. *Hypertension* 2001;19:883–891.

31. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjelsen SE, Julins S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahlöf B. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. *JAMA* 2006;296:1242–1248.
32. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological Mechanisms of Atrial Fibrillation: A Translational Appraisal. *Physiol Rev* 2011;91:265–325.
33. Stollberger C, Finsterer J, Ernst G, Schneider BZ. Is left atrial appendage occlusion useful for prevention of Stroke or embolism in atrial fibrillation ? *Kardiol* 2002;91:376–379.
34. Thrall G, Lane D, Carroll D, Lip GYH. Quality of life in patients with atrial fibrillation: a systematic review. *Am J Med* 2006;119:448 e1–e19.
35. Tomita T, Takei M, Saikawa Y, Hanaoka T, Uchikawa S, Tsutsui H, Aruga M, Miyashita T, Yazaki Y, Imamura H, Kinoshita O, Owa M, Kubo K. Role of autonomic tone in the initiation and termination of paroxysmal atrial fibrillation in patients without structural heart disease. *Clin Cardiol* 2003;26:341–347.
36. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward BJ. Risks for atrial fibrillation and congestive heart failure in patients ≥ 65 years of age with abnormal left ventricular diastolic relaxation. *Am J Cardiol* 2004;93:54–58.
37. Verdecchia P, Reboldi G, Gattobigio R, Rentivoglio M, Borgioni C, Angeli F, Carluccio E, Sardone MG, Porcellati S. Atrial fibrillation in Hypertension: predictors and outcome. *Hypertension* 2003;41:218–223.